Wednesday, January 16, 2008

February 2008

The US Food and Drug Governing body (FDA) approved Symbyax (olanzapine and fluoxetine HCl) for use as a change of integrity intersection in the direction of depressive episodes associated with bipolar condition.
Also approved by the FDA was the use of Zyprexa

(olanzapine) in the long-term attention of bipolar I physical condition.

Eloxatin (oxaliplatin) shot in accumulation with infusional 5-fluorouracil (5-FU) and leucovorin (LV) was approved for the tending of patients previously untreated for advanced colorectal planetary house.

This month’s array reviews FDA new trade good approvals and labeling changes for:

AntidepressantsSymbyax (olanzapine and fluoxetine HCl) Capsules

Anti-infective AgentsZithromax (azithromycin) Oral Suspension system and Tablets

Antineoplastic AgentsEloxatin (oxaliplatin) Medical careFaslodex (fulvestrant) Intromission

Antipsychotic AgentsSeroquel (quetiapine fumarate) TabletsZyprexa (olanzapine) Tablets

Cardiovascular AgentsNorvasc (amlodipine besylate) Tablets

Department 1 of 6 Jane S.
Ricciuti, RPh, MS
, Top dog Trained worker, AdComm Bulletin, and U.S.
This is a part of article February 2008 Taken from "Buy Prozac Fluoxetine Online" Information Blog

No comments: